Physician profile
Andrew P Chen
NPI 1912014739
$3,169.54
in general payments reported to CMS, 2019-2025
24 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $308 · 2021: $496 · 2022: $688 · 2023: $463 · 2024: $309 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $705.14 | 2019-2025 | Hydrus Microstent, Rocklatan, Precision 1 |
| Abbvie INC. | $360.61 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Allergan, INC. | $336.92 | 2019-2022 | |
| Horizon Therapeutics Plc | $188.85 | 2021-2023 | Tepezza |
| Oyster Point Pharma, INC. | $182.44 | 2022-2024 | Tyrvaya, Tyrvaya, Ryzumvi |
| New World Medical,INC. | $181.91 | 2025 | Clearpath, Via360, Streamline |
| Amgen INC. | $152.79 | 2025 | Uplizna |
| Apellis Pharmaceuticals, INC. | $144.10 | 2023-2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $110.73 | 2024-2025 | Xdemvy |
| Nestle Healthcare Nutrition INC. | $109.26 | 2021 | |
| Ivantis, INC | $100.17 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $98.54 | 2019-2020 | |
| Genentech USA, INC. | $92.34 | 2022-2025 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $85.72 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $77.42 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $62.05 | 2021-2022 | |
| Glaukos Corporation | $44.48 | 2022 | |
| Bausch & Lomb Americas INC. | $24.28 | 2023 | Vyzulta |
| Optos, INC. | $22.74 | 2020 | |
| Rxsight INC | $21.67 | 2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $18.68 | 2021 | |
| Iridex Corporation | $17.99 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Shire North American Group INC | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.